
Alesi Surgical, an innovative company located in Cardiff, Wales, United Kingdom, has recently made headlines by successfully raising £5 million in funding aimed at advancing its groundbreaking technology designed specifically to manage smoke generated by surgical tools within operating theatres. This funding round was spearheaded by Mercia Ventures and included investments from established backers such as IP Group and Panakès Partners. The infusion of capital will be instrumental as Alesi Surgical seeks to expand its sales efforts in the competitive United States market while also pursuing necessary regulatory approvals for its unique products across Europe and Japan.
At the helm of Alesi Surgical is CEO Dominic Griffiths, who has been pivotal in guiding the company’s vision and operational strategies.
Alesi manufactures a sophisticated system that employs electrical filtration methods to effectively remove surgical smoke from the air, thus ensuring a safer operating environment. Their latest offering, Ultravision2, has received FDA approval and is a versatile platform technology designed to seamlessly integrate with both surgical tools and existing theatre equipment. This is crucial for modern hospitals that require adaptability and efficiency in their surgical practices.
The company’s commitment to innovation is further underscored by its first integrated tool, specifically engineered for laparoscopic surgery, which has already secured FDA approval. Additionally, the recent launch of the IonPencil has broadened Alesi's offerings to include smoke management solutions applicable to all surgical procedures that generate smoke. With its original Ultravision system previously utilized in over 40,000 procedures, Alesi Surgical, a proud spin-out from Cardiff University, continues to enhance surgical safety and operational efficiency, all while operating from its base at the Cardiff Medicentre with a dedicated team of 15 skilled professionals.
Click here for a full list of 7,526+ startup investors in the UK